Jefferies Maintains Bullish View on Array BioPharma (ARRY) Following Update from Society for Melanoma Research
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $8 price target on Array BioPharma (NASDAQ: ARRY) following an updates ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
